Immunic
PublicImmunic is now publicly traded
The data on this page reflects Immunic's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Post-IPO Financing
Mar 4, 2026
Total Funding Raised
$200M
Company Overview
Immunic is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.
AI Layer
Non-AI
Keywords
Immunic Comparables
Compare Immunic with similar companies based on industry and business-model similarity.
No public comparables are available for Immunic. Request access to learn about comparables coverage.
Request accessImmunic Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Post-IPO Financing | Mar 4, 2026 |
Immunic Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Post-IPO Financing |
| Janus Henderson Group | Post-IPO Financing |
| RA Capital Management | Post-IPO Financing |
| TCG Crossover | Post-IPO Financing |
| Coastlands Capital LP | Post-IPO Financing |
| OrbiMed | Post-IPO Financing |
| BVF Partners L.P. | Post-IPO Financing |
Immunic Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access